Can You Take Fluvoxamine While on Eliquis (Apixaban)?
Yes, you can take fluvoxamine with Eliquis (apixaban), but this combination requires caution and close monitoring due to increased bleeding risk from two distinct mechanisms: fluvoxamine's effect on platelet function and its potential to increase apixaban levels through drug metabolism interactions.
Understanding the Interaction
Two Mechanisms of Concern
Pharmacodynamic Interaction (Bleeding Risk): Fluvoxamine, like all SSRIs, can impair platelet serotonin function and increase bleeding risk independent of any effect on apixaban levels 1. The FDA label for Eliquis specifically warns that SSRIs increase bleeding risk when combined with anticoagulants 2.
Pharmacokinetic Interaction (Drug Levels): Fluvoxamine is a moderate inhibitor of CYP3A4 and potentially affects P-glycoprotein (P-gp) 1, 3. Since apixaban is metabolized by CYP3A4 (and is a P-gp substrate), fluvoxamine could theoretically increase apixaban levels 2. However, the clinical significance of this metabolic interaction appears limited - fluvoxamine is only a weak-to-moderate CYP3A4 inhibitor, not a strong one 4.
Clinical Recommendations
Dosing Considerations
No dose adjustment of apixaban is required when combining with fluvoxamine, as the FDA label only mandates dose reduction for combined P-gp AND strong CYP3A4 inhibitors (like ketoconazole, itraconazole, ritonavir, or clarithromycin) 2. Fluvoxamine does not meet this threshold.
The 2024 ACC/AHA/ACCP/HRS guidelines confirm that apixaban requires "no dose adjustment with concomitant use of" moderate CYP3A4 inhibitors 5.
Monitoring Strategy
You should:
- Be vigilant for signs of bleeding (unusual bruising, prolonged bleeding from cuts, nosebleeds, blood in urine/stool, severe headaches) 2
- Avoid adding other medications that increase bleeding risk (NSAIDs like ibuprofen, aspirin, other antiplatelet agents) 1, 2
- Report any bleeding symptoms immediately to your physician
- Ensure your prescribing physician knows you're taking both medications
Important Caveats
Higher risk situations where extra caution is warranted:
- If you're already on the reduced dose of apixaban (2.5 mg twice daily) - avoid adding strong CYP3A4/P-gp inhibitors entirely 2
- If you have impaired kidney function (CrCl 15-50 mL/min) - the combination warrants closer monitoring 5
- If you're elderly (≥80 years) or low body weight (≤60 kg) - already at higher bleeding risk 5
- If you have a history of bleeding events 1
The Evidence Base
The 2020 AACAP guideline notes that fluvoxamine has "greater potential for drug-drug interactions" among SSRIs due to its effects on multiple CYP enzymes (CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6) 1. A 2020 systematic review confirmed that fluoxetine and fluvoxamine carry the highest interaction risk with anticoagulants among SSRIs, though this was primarily studied with warfarin 4.
However, the pharmacokinetic interaction with apixaban appears less clinically significant than initially feared. A 2020 analysis of drug interactions with apixaban found that most clinically relevant interactions were pharmacodynamic (affecting bleeding/clotting directly) rather than pharmacokinetic (affecting drug levels) 6.
Bottom Line
The combination is not contraindicated and does not require apixaban dose adjustment, but demands heightened awareness of bleeding risk. The primary concern is the additive bleeding risk from fluvoxamine's effect on platelet function combined with apixaban's anticoagulant effect, rather than a major change in apixaban drug levels. Inform all your healthcare providers about this combination and maintain vigilance for bleeding symptoms 2.